Yoneda N, Irahara M, Saito S, Uemura H, Aono T. Usefulness of recombinant human prolactin for treatment of poor puerperal lactation in a rat model. Eur J Endocrinol 1995;133:613\p=n-\7. ISSN 0804\p=n-\ 4643 Recombinant human prolactin (r-hPRL) was produced by a line of murine C127 cells transfected with human PRL gene. To assess the biological efficacy of r-hPRL in vivo, we studied its influence on milk secretion using a rat model in which lactation was reduced by bromocriptine treatment. Puerperal rats were injected daily for 9 days after delivery with bromocriptine or bromocriptine plus r-hPRL, and lactational performance was assessed by weighing the pups. (4, 5) .
Recombinant human prolactin (r-hPRL) was produced by a line of murine C127 cells transfected with human PRL gene. To assess the biological efficacy of r-hPRL in vivo, we studied its influence on milk secretion using a rat model in which lactation was reduced by bromocriptine treatment. Puerperal rats were injected daily for 9 days after delivery with bromocriptine or bromocriptine plus r-hPRL, and lactational performance was assessed by weighing the pups. The concentrations of rat and human PRL in rat serum were measured by specific radioimmunoassays and the mammary glands were examined on postpartum day 10. Daily injection of bromocriptine (0.1 mg/rat) significantly reduced the endogenous level of rat PRL and impaired the weight gain of the pups. Administration of r-hPRL increased the serum level of human PRL. Daily injections of r-hPRL (50 \g=m\g/rat, twice a day) restored lactational performance and significantly increased the weight of the pups. The detrimental effect of bromocriptine on the mammary glands, assessed by both weight and histological appearance, was reversed by administration of r-hPRL. These results demonstrate that r-hPRL is biologically active in vivo and replacement therapy of r-hPRL is effective in improving the lactational performance in bromocriptine-treated rats, and also that r-hPRL may be useful for the treatment of women with poor lactation.
Naoto Yoneda, Department of Obstetrics and Gynecology, School ofMedicine, The University of Tokushima, 3\ x=r eq-\ 18-15 Kuramoto, Tokushima 770, Japan Breast feeding is known to be better than bottle feeding nutritionally, immunologically and in the formation of a mother-infant bond. Therefore, it is considered best for the development of babies (1) (2) (3) and there is increasing awareness of the need to treat women who have poor puerperal lactation (4, 5) .
Prolactin (PRL) is synthesized by the lactotropes in the anterior pituitary and is well known to play a role in stimulating milk production. When puerperal women nurse their babies, PRL is released from the pituitary gland within 3Omin from the start of suckling and strongly stimulates milk production (6). Furthermore, it plays another important role in the establishment and maintenance of breast feeding. The initiation of milk secretion in the early puerperal period is closely related to an increase in the serum PRL level induced by adequate suckling (7, 8) . Puerperal women with poor PRL secretion thus have difficulty in breast feeding, and therefore there is a need for PRL in such women (4, 5) .
Recently, recombinant human prolactin (r-hPRL) has been produced by a line of murine C127 cells transfected with human PRL gene (9) . This Changes in weight of pups after r-hPRL injection Figure 3 shows the changes in mean weights of the pups in the three groups from postnatal days 0 to 10 (20, 21) . The structure of the PRL receptor has been identified recently by screening cDNA libraries (22, 23) (Fig. 1) . The increase of PRL during suckling was prevented for several hours by bromocriptine, and daily treatment with bromocriptine impaired lactational performance and decreased the weight gain of the pups (Fig. 3) . After subcutaneous injection of r-hPRL (50/xg/rat) the serum hPRL level promptly increased to a maximum of 2 3 pg/l in 2 h then decreased to less than half this level after about 4 h and to almost zero after 8 h (Fig. 2) . Data 
